News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Daiichi Sankyo Co Ltd. Posts $3.7 Billion Q3 Loss on Ranbaxy Pharmaceuticals Inc.
January 30, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TOKYO, Jan 30 (Reuters) - Daiichi Sankyo, Japan's third-largest drugmaker, posted a $3.7 billion quarterly loss and forecast its first annual loss, hit by a slide in the value of its stake in India's Ranbaxy Laboratories.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Asia
Daiichi Sankyo
MORE ON THIS TOPIC
Earnings
Moderna’s FDA Challenges Stymie Breakeven Goal in ‘Fresh and Fluid’ Situation
February 13, 2026
·
5 min read
·
Annalee Armstrong
Gene therapy
Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp
February 13, 2026
·
3 min read
·
Dan Samorodnitsky
Obesity
Lilly Prepares $1B+ Orforglipron Stock Ahead of Approval as Novo Brings Wegovy Pill Overseas
February 13, 2026
·
2 min read
·
Tristan Manalac
Earnings
All Eyes on Vertex’s Kidney Franchise, as Painkiller Journavx Tops Half a Million Scripts
February 13, 2026
·
2 min read
·
Tristan Manalac
